Genmab — Maj 2018
-
-
Angående solide og flere patienter: "We also have possibilities of expanding that study by adding in more patients. And I think that’s up to Janssen to see whether they do that. And we have just recently started interacting with Janssen about what level of detail we can potentially use in the first communication in the second half of this year. And that will likely include in different subsets of patients because we’re doing a lot of biomarker analysis in that study, looking at overall response"
-
Only Sarcoma was new https://clinicaltrials.gov/ct2/history/NCT02988817?A=5&B=6&C=Side-by-Side
-
Sagsanlæg Morphosys. https://medwatch.dk/secure/Medicinal___Biotek/article10586602.ece
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind